EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Price, Forecast & Analysis
NASDAQ:EPRX • CA29842P1053
EPRX Key Statistics, Chart & Performance
The current stock price of EPRX is 8.5 USD. In the past month the price decreased by -5.66%. In the past year, price increased by 132.88%.
EPRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EPRX. When comparing the yearly performance of all stocks, EPRX is one of the better performing stocks in the market, outperforming 95.56% of all stocks.
EPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPRX. No worries on liquidiy or solvency for EPRX as it has an excellent financial health rating, but there are worries on the profitability.
EPRX Financial Highlights
Over the last trailing twelve months EPRX reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS decreased by -6.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.81% | ||
| ROE | -32.63% | ||
| Debt/Equity | 0 |
EPRX Forecast & Estimates
8 analysts have analysed EPRX and the average price target is 10.75 USD. This implies a price increase of 26.46% is expected in the next year compared to the current price of 8.5.
EPRX Ownership
EPRX Latest News, Press Relases and Analysis
EPRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EPRX
Company Profile
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Company Info
EUPRAXIA PHARMACEUTICALS INC
201-2067 Cadboro Bay Rd.
Victoria BRITISH COLUMBIA CA
Employees: 33
Phone: 12505903968
EUPRAXIA PHARMACEUTICALS INC / EPRX FAQ
Can you describe the business of EUPRAXIA PHARMACEUTICALS INC?
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
What is the current price of EPRX stock?
The current stock price of EPRX is 8.5 USD. The price increased by 4.68% in the last trading session.
What is the dividend status of EUPRAXIA PHARMACEUTICALS INC?
EPRX does not pay a dividend.
What is the ChartMill rating of EUPRAXIA PHARMACEUTICALS INC stock?
EPRX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does EUPRAXIA PHARMACEUTICALS INC belong to?
EUPRAXIA PHARMACEUTICALS INC (EPRX) operates in the Health Care sector and the Biotechnology industry.
Would investing in EUPRAXIA PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EPRX.